Economy/Home · Economy

[Breaking] NexAI Shares Fall 4.38% on First Day of KOSDAQ Listing... Attention Turns to New Drug Development for Immune Oncology Non-Responders

NexAI was listed on the KOSDAQ market on the 12th. As of 9 a.m. that day, the stock price stood at 7,650 won, down 4.38% from the initial public offering price of 8,000 won. Attention is focused on how the stock will perform on its first day of trading. In particular, the company's technology for i

Wooil Shim
Staff Reporter
8 min read
[Breaking] NexAI Shares Fall 4.38% on First Day of KOSDAQ Listing... Attention Turns to New Drug Development for Immune Oncology Non-Responders
CBC News

NexAI was listed on the KOSDAQ market on the 12th. As of 9 a.m. that day, the stock price stood at 7,650 won, down 4.38% from the initial public offering price of 8,000 won. Attention is focused on how the stock will perform on its first day of trading.

In particular, the company's technology for identifying the causes of non-response to immuno-oncology therapy and developing new drugs targeting them is expected to emerge as a key factor in evaluating its corporate value.

■ About Four Months to Listing... From Preliminary Review to Subscription

NexAI filed for a preliminary listing review on July 21 and received approval on September 17. It then submitted its securities registration statement on September 28 and conducted demand forecasting for institutional investors from October 22 to 28. Public subscription for retail investors was held for two days from November 3 to 4, followed by the allotment announcement and payment/refund procedures on the 6th.

■ Price Limit Band: 4,800 to 32,000 Won

Based on the IPO price of 8,000 won, the price range in which the stock can move on its first day of trading is between 4,800 and 32,000 won. The price limit on the listing day for newly listed stocks in Korea is set at 60% to 400% of the IPO price.

Accordingly, if the stock reaches the upper limit of 32,000 won on the first day, it would represent a 300% gain over the IPO price. Conversely, if it falls to the lower limit of 4,800 won, it would incur a 40% loss.

■ Core Business: Developing Treatments for Immune Oncology Non-Responders

NexAI's core business is developing treatments for patients who do not respond to immuno-oncology drugs. Immuno-oncology drugs are therapies that induce the human immune system to attack cancer cells, but some patients show insufficient treatment response or develop resistance during the course of treatment.

To overcome these limitations, NexAI is identifying causal factors behind non-response to immuno-oncology drugs and researching anticancer new drugs that directly target them. The company's in-house drug development platform, NEXORA(TM), is used to elucidate the molecular mechanisms and key factors of immuno-oncology drug resistance. Based on this, the company is pursuing the development of First-in-Class drugs with mechanisms of action differentiated from existing therapies.

While existing immuno-oncology drug development has focused on enhancing anticancer immune activity, NexAI differentiates itself by concentrating its research capabilities on discovering new mechanisms that cause treatment non-response and controlling them. The company is also exploring various collaboration opportunities, including joint research and development and technology transfers with domestic and international pharmaceutical companies. Its key challenges include commercializing research outcomes in the drug development process and expanding external partnerships.

■ Investment Cautions... Technical Feasibility Requires Separate Verification

However, the value of a drug development company can vary depending on its R&D stage, clinical trial results, and whether technology transfer agreements are concluded. Whether the technical feasibility confirmed at the research stage translates into actual drug approval and commercial success requires separate verification.

Following the listing, attention is expected to focus on the development progress of key drug candidates, R&D achievements, and potential collaborations with global pharmaceutical companies. In the first trading session on the 12th, key points of interest include the opening price relative to the IPO price of 8,000 won, intraday volatility, and trading volume.

[Some AI assistance was used in producing this article. This article does not recommend buying or selling any specific stock; investment decisions and responsibilities rest with the investor.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.